DOI: https://doi.org/10.22141/2308-2097.52.3.2018.141840

Changes in prostaglandin levels in the blood serum of patients with gastroesophageal reflux disease on the background of type 2 diabetes mellitus

Ye.S. Sirchak, M.P. Stan

Abstract


Background. Digestive organ damage in patients with diabetes mellitus (DM) is based on several mechanisms: autonomic nervous system dysfunction, angiopathy, dysregulation of secretion and inactivation of hormones and increments. The purpose was to study the features of changes in prostaglandin (Pg) levels (I2 and F2α) in the blood serum of patients with gastroesophageal reflux disease (GERD) on the background of type 2 DM depending on the body mass index violation. Materials and methods. The study involved 54 patients with type 2 DM and GERD (group I). The comparison group included 22 patients with GERD (group II). The patients had their blood serum examined and indicators of Pg F2α and 6-keto-prostaglandin F1α (blood prostacyclin — Pg I2) determined. Results. Increased levels of prostaglandins in both groups of patients were detected, but more significant changes were observed in group I. Attention is called to a more significant increase in Pg I2 concentration compared with Pg F2α, especially in patients with GERD on the background of type 2 DM (3.4 times compared with 2.1 times in group I). Patients with GERD revealed the increased levels of Pg I2 by 2.2 times, while Pg F2α is only 1.6 times higher. In the combination of several pathological states (type 2 DM, GERD, increased body mass index), there is a more significant increase in the concentration of prostacyclin, which also depends on the duration of the disease. Conclusions. In patients with GERD, an increase in the levels of prostaglandins F2αand I2 in the blood serum has been detected. The combination of GERD and type 2 DM is accompanied by a more significant increase in the concentration of prostaglandins, especially Pg I2, in the blood serum. The correlation was established between the duration of type 2 DM mellitus, excessive body weight and the dynamics of Pg I2 level in the blood serum of patients with GERD on the background of type 2 diabetes mellitus.


Keywords


gastroesophageal reflux disease; type 2 diabetes mellitus; prostaglandins

Full Text:

PDF

References


Mayev IV, Yurenev GL, Busarova GA. Gastroesophageal reflux disease (Review of XVII Russian gastroenterological week. 2011, October 10-12; Moscow). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2012;22(5):13-23. (in Russian).

Mayev IV, Yurenev GL, Dicheva DT, et al. Influence of psychocorrection on the course of the disease and life quality in patients with gastroesophageal reflux disease, bronchial asthma and their combination. Meditsinskiy Sovet. 2012;(6):56-63. (in Russian).

Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2013 Mar;108(3):308-28; quiz 329. doi: 10.1038/ajg.2012.444.

Frazzoni M, Manta R, Mirante VG, Conigliaro R, Frazzoni L, Melotti G. Esophageal chemical clearance is impaired in gastro-esophageal reflux disease - a 24-h impedance-pH monitoring assessment. Neurogastroenterol Motil. 2013 May;25(5):399-406, e295. doi: 10.1111/nmo.12080.

Dragomiretskaia NV. Ways to improve GERD therapy. Zdorov’ja Ukrai'ny. Gastroenterologija, Gepatologija, Koloproktologija. 2016;(42):21. (in Russian).

Lee SD, Keum B, Chun HJ, Bak YT. Gastroesophageal Reflux Disease in Type II Diabetes Mellitus With or Without Peripheral Neuropathy. J Neurogastroenterol Motil. 2011 Jul;17(3):274-8. doi: 10.5056/jnm.2011.17.3.274.

Makovetskaia M. The newest technologies in theoretical and practical gastroenterology. Zdorov’ja Ukrai'ny. 2016;(386-387):20-21. (in Russian).

Kusnir IE. GERD in obese patients: pathophysiological mechanisms of development, features of the course and approaches to therapy. Zdorov’ja Ukrai'ny. Gastroenterologija, Gepatologija, Koloproktologija. 2013;(29):70-71. (in Russian).

Krleza-Jerić K, Lemmens T. 7th revision of the Declaration of Helsinki: good news for the transparency of clinical trials. Croat Med J. 2009 Apr;50(2):105-10. doi: 10.3325/cmj.2009.50.105.

Emanuel EY. The Eighth Revision of the Declaration of Helsinki: What Should be Done? Available from: https://www.wma.net/presentation_emanuel/. Accessed: January 20, 2017.

World Health Organization. Global Database on Body Mass Index (BMI). Available from: http://www.who.int/nutrition/databases/bmi/en/.

Hobzej MK, Gul’chij MV, Stepanenko AV, et al. Unifikovanyj klinichnyj protokol pervynnoi' ta vtorynnoi' (specializovanoi') medychnoi' dopomogy. Сukrovyj diabet 2 typu [Unified clinical protocol for primary and secondary (specialized) medical aid. Diabetes mellitus type 2]. Kyiv; 2012. 118 p. (in Ukrainian).

Gul’chij MV, Matjuha LF, Netjazhenko VZ, et al. Cukrovyj diabet 2 typu. Adaptovana klinichna nastanova, zasnovana na dokazah [Diabetes mellitus type 2. Adapted clinical guideline based on evidence]. Kyiv; 2012. 343 p. (in Ukrainian).

Hobzej MK, Harchenko NV, Lishhyshyna OM, et al. Unifikovanyj klinichnyj protokol pervynnoi' ta vtorynnoi' (specializovanoi') medychnoi' dopomogy. Gastroezofageal'na refljuksna hvoroba [Unified clinical protocol for primary and secondary (specialized) medical care. Gastroesophageal reflux disease]. Kyiv; 2013. 32 p. (in Ukrainian).

Sun H, Yi L, Wu P, Li Y, Luo B, Xu S. Prevalence of Gastroesophageal Reflux Disease in Type II Diabetes Mellitus. Gastroenterol Res Pract. 2014;2014:601571. doi: 10.1155/2014/601571.

Lee SD, Keum B, Chun HJ, Bak YT. Gastroesophageal Reflux Disease in Type II Diabetes Mellitus With or Without Peripheral Neuropathy. J Neurogastroenterol Motil. 2011 Jul;17(3):274-8. doi: 10.5056/jnm.2011.17.3.274.

Ha JO, Lee TH, Lee CW, et al. Prevalence and Risk Factors of Gastroesophageal Reflux Disease in Patients with Type 2 Diabetes Mellitus. Diabetes Metab J. 2016 Aug;40(4):297-307. doi: 10.4093/dmj.2016.40.4.297.

Takeuchi K. Prostaglandin EP receptors and their roles in mucosal protection and ulcer healing in the gastrointestinal tract. Adv Clin Chem. 2010;51:121-44.

Chernyshov VA. Insulin therapy in type 2 diabetes mellitus: is there antiatherogenic or proatherogenic effect? Ukrainian Therapeutical Journal. 2013;(4):5-12. (in Russian).

Serhiyenko VA, Azhmi S, Serhiyenko AA. Comparison of efficiency of omega-3 polyunsaturated fatty acids, statins and their combination on lipids parameters, vascular-thrombocyte homeostasis and heart rate variability parameters in patients with type 2 diabetes mellitus and cardiovascular autono. Mìžnarodnij endokrinologìčnij žurnal. 2017;13(5):315-323. doi: 10.22141/2224-0721.13.5.2017.110020. (in Ukrainian).

Dorosh EG, Kravchun NA. 8-Iso-prostaglandin level and its relation to metabolic parameters in patients with type 2 diabetes mellitus in combination with non-alcoholic fatty liver disease. Practical medicine. 2013;(76):111-116. (in Russian).




Copyright (c) 2018 GASTROENTEROLOGY

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2018

 

   Seo анализ сайта